Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Monte Rosa Therapeutics Inc (GLUE)

Monte Rosa Therapeutics Inc (GLUE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 513,613
  • Shares Outstanding, K 61,437
  • Annual Sales, $ 0 K
  • Annual Income, $ -135,350 K
  • EBIT $ -129 M
  • EBITDA $ -123 M
  • 60-Month Beta 1.30
  • Price/Sales 37.75
  • Price/Cash Flow N/A
  • Price/Book 2.48

Options Overview Details

View History
  • Implied Volatility 105.47% ( +8.40%)
  • Historical Volatility 203.66%
  • IV Percentile 29%
  • IV Rank 19.50%
  • IV High 486.85% on 07/19/24
  • IV Low 13.06% on 10/09/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 96
  • Volume Avg (30-Day) 1,220
  • Put/Call OI Ratio 0.34
  • Today's Open Interest 5,387
  • Open Int (30-Day) 8,001

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.27
  • Number of Estimates 3
  • High Estimate -0.20
  • Low Estimate -0.37
  • Prior Year -0.58
  • Growth Rate Est. (year over year) +53.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.76 +85.71%
on 10/23/24
12.40 -28.71%
on 10/28/24
+3.39 (+62.20%)
since 10/21/24
3-Month
4.59 +92.38%
on 10/09/24
12.40 -28.71%
on 10/28/24
+2.31 (+35.38%)
since 08/21/24
52-Week
2.91 +203.72%
on 11/27/23
12.40 -28.71%
on 10/28/24
+5.86 (+196.64%)
since 11/21/23

Most Recent Stories

More News
Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference

GLUE : 8.80 (+5.26%)
Monte Rosa Therapeutics: Q3 Earnings Snapshot

Monte Rosa Therapeutics: Q3 Earnings Snapshot

GLUE : 8.80 (+5.26%)
Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

GLUE : 8.80 (+5.26%)
Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

GLUE : 8.80 (+5.26%)
Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors

GLUE : 8.80 (+5.26%)
Monte Rosa Therapeutics: Q2 Earnings Snapshot

Monte Rosa Therapeutics: Q2 Earnings Snapshot

GLUE : 8.80 (+5.26%)
3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street

Analysts have high hopes for these three innovation companies in 2024.

BEAM : 24.00 (-2.00%)
EWTX : 32.21 (+0.81%)
GLUE : 8.80 (+5.26%)
Pre-Market Brief: Stocks Climb As Investors Await FOMC Minutes

March S&P 500 futures (ESH23) are trending up +1.12% this morning after three major U.S. benchmark indices closed lower on 2022’s last trading day as market participants braced for the new year with...

ESH23 : 3,957.05s (-0.09%)
LI : 22.57 (-0.92%)
NIO : 4.71 (+1.29%)
TSLA : 340.18 (-0.54%)
FMS : 22.01 (+1.01%)
GLUE : 8.80 (+5.26%)
Monte Rosa Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates

– Submitted Investigational New Drug (IND) Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader for the Treatment of Myc-driven Solid Tumors...

GLUE : 8.80 (+5.26%)
Monte Rosa Therapeutics Reports First Quarter 2022 Financial Results and Business Updates

– Presented Preclinical Data at AACR Annual Meeting Supporting Clinical Development of MRT-2359 as Potent and Selective GSPT1-directed Molecular Glue...

GLUE : 8.80 (+5.26%)

Business Summary

Monte Rosa Therapeutics Inc. is a biotechnology company. It involved in developing a portfolio of novel small molecule precision medicines which employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. Monte Rosa Therapeutics Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 9.21
2nd Resistance Point 8.91
1st Resistance Point 8.64
Last Price 8.80
1st Support Level 8.07
2nd Support Level 7.77
3rd Support Level 7.50

See More

52-Week High 12.40
Last Price 8.80
Fibonacci 61.8% 8.78
Fibonacci 50% 7.66
Fibonacci 38.2% 6.54
52-Week Low 2.91

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar